MLTX – moonlake immunotherapeutics - class a ordinary shares (US:NASDAQ)
Stock Stats
News
MoonLake Immunotherapeutics (MLTX) was upgraded by Wolfe Research from "underperform" to "outperform". They now have a $24.00 price target on the stock.
MoonLake Immunotherapeutics (MLTX) was upgraded by Rothschild & Co Redburn from "neutral" to "buy". They now have a $40.00 price target on the stock.
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? [Yahoo! Finance]
MoonLake Immunotherapeutics (MLTX) had its price target raised by Royal Bank Of Canada from $12.00 to $13.00. They now have a "sector perform" rating on the stock.
Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update [Yahoo! Finance]
Form 10-K MoonLake Immunotherapeut For: Dec 31
Form 8-K MoonLake Immunotherapeut For: Feb 18
Form SCHEDULE 13G MoonLake Immunotherapeut Filed by: Cormorant Asset Management, LP
Form 4 MoonLake Immunotherapeut For: Jan 07 Filed by: Reich Kristian
Form 4 MoonLake Immunotherapeut For: Jan 07 Filed by: Bodenstedt Matthias
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.